Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
NCT ID: NCT01495741
Last Updated: 2022-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42 participants
OBSERVATIONAL
2013-07-01
2017-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
NCT01498770
An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)
NCT01765127
40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
NCT00159783
Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)
NCT00764478
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
NCT00159796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asenapine
Participants prescribed asenapine
No interventions assigned to this group
Risperidone Comparator
Participants prescribed risperidone
No interventions assigned to this group
Olanzapine Comparator
Participants prescribed olanzapine
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of schizophrenia
Exclusion Criteria
* A prior and/or concomitant diagnosis of bipolar disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-8274-110
Identifier Type: OTHER
Identifier Source: secondary_id
P08307
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.